North America Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032

North America Colorectal Cancer Screening Tests Market Outlook

The North America colorectal cancer screening tests market size was valued at USD 5.94 billion in 2023. The market is further projected to grow at a CAGR of 5.6% between 2024 and 2032, reaching a value of USD 9.78 billion by 2032.

Key Takeaways

• The American Cancer Society's estimates for colorectal cancers in the United States of America for 2024 are around 106,590 new cases of colon cancer and 46,220 new cases of rectal cancer.

• As per industry reports, in 2021, approximately 24,800 cases of colorectal cancer had been diagnosed in Canada.

• According to the Canadian Cancer Society, colorectal cancer is the fourth most common cancer in the country.

According to the North America colorectal cancer screening tests market report, a rising number of younger people are being diagnosed with colorectal cancer in North America. Factors contributing to an increase in colorectal cancer are an unhealthy diet, lack of physical activity, and a rise in smoking and alcohol consumption as well as genetics or family history. Symptoms of colorectal cancer include blood in stool, changes in bowel habits, and unexplained weight loss. Canadian provinces conduct routine colorectal cancer screening programs, which aids the market growth.

According to the North America colorectal cancer screening tests market analysis, the fecal immunochemical test (FIT) is an easy-to-use stool test that can also be done at home. It can help patients find colorectal cancer early, as well as precancerous conditions that if untreated might become colorectal cancer. In Canada, Ontario, and British Columbia recommend FIT screening every two years, while people living in Alberta are eligible for annual FIT screening. The U.S. Preventive Services Task Force recommends that adults aged between 45 to 75 be regularly screened for colorectal cancer. The colorectal cancer survival rate is rising in Canada and the United States supported by earlier detection of the cancer through routine examinations and screening and due to advances in treatments.

Market Segmentation

North America Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032 offers a detailed analysis of the market based on the following segments.

Market Breakup by Screening Tests

• Stool-Based Tests
  • Fecal Immunochemical Test (FIT)
  • Fecal Occult Blood Test (FOBT)
  • Stool DNA Test

• Colonoscopy

• CT Colonography (Virtual Colonoscopy)

• Flexible Sigmoidoscopy

• Others

Market Breakup by End User

• Hospitals

• Diagnostic Centres/Laboratories

• Others 

Market Breakup by Country

• United States of America

• Canada

Competitive Landscape

The key players in the colorectal cancer screening tests market in North America are producing highly efficient colorectal cancer screening tests.

• Abbott Laboratories

• 3T Medical Complete Systems  

• Epigenomics AG                 

• Exact Sciences Corporation 

• Roche Diagnostics Corporation         

• Siemens AG            

• Sysmex Inostics, Inc.                

• EKF Diagnostics Holdings Plc    

• Laboratory Corporation of America® Holdings.    

• LetsGetChecked Inc    

• Others

Key Highlights of the Report

North America Colorectal Cancer Screening Tests Market Report Snapshots

North America Colorectal Cancer Screening Tests Market Size

North America Colorectal Cancer Screening Tests Companies